来自 Rebecca Heist 医生（@MGHThoracicOnc）在 #ESMO26 上传达的重要信息！
MET 扩增可能导致肺癌对 EGFR 靶向治疗产生耐药。疾病进展时重复进行生物标志物检测，可能发现新的治疗机会，包括 EGFR + MET 联合抑制。
#METCrusaders #NSCLC #LungCancer #METamplification #BiomarkerTesting #lcsm
0 赞 · 0 转发 · 0 回复
Phase 1 first-in-human (FIH) results of YL211, a c-Met targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors
https://esmocongress.esmo.orgClinical and genomic landscape of de novo MET amplified NSCLC (LC-SCRUM-Asia)
https://esmocongress.esmo.orgMCLA-129 in patients (pts) with EGFR-mutant advanced non-small cell lung cancer (NSCLC) with MET overexpression and/or amplification: Results from a phase II study
https://esmocongress.esmo.orgPhase 2 study of SHR-1826, a c-MET directed antibody-drug-conjugate, combined with PD-L1 inhibitor and CTLA-4 inhibitor in previously treated advanced/metastatic non-squamous NSCLC
https://esmocongress.esmo.org- **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
https://esmocongress.esmo.org来源：METCrusaders · x.com